215 related articles for article (PubMed ID: 32578333)
1. Current and future strategies for treatment of ovarian clear cell carcinoma.
Ogasawara A; Sato S; Hasegawa K
J Obstet Gynaecol Res; 2020 Sep; 46(9):1678-1689. PubMed ID: 32578333
[TBL] [Abstract][Full Text] [Related]
2. Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma.
Takahashi K; Takenaka M; Kawabata A; Yanaihara N; Okamoto A
Int J Clin Oncol; 2020 Mar; 25(3):425-431. PubMed ID: 31989349
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues.
Gan M; Tai Z; Yu Y; Zhang C; Xu J
PeerJ; 2023; 11():e14653. PubMed ID: 36721777
[TBL] [Abstract][Full Text] [Related]
4. Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer.
Fujiwara S
Jpn J Clin Oncol; 2023 Jul; 53(8):664-672. PubMed ID: 37288485
[TBL] [Abstract][Full Text] [Related]
5. Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
Oda K; Hamanishi J; Matsuo K; Hasegawa K
Gynecol Oncol; 2018 Nov; 151(2):381-389. PubMed ID: 30217369
[TBL] [Abstract][Full Text] [Related]
6. A clearer view on ovarian clear cell carcinoma.
De Pauw A; Naert E; Van de Vijver K; Philippe T; Vandecasteele K; Denys H
Acta Clin Belg; 2022 Aug; 77(4):792-804. PubMed ID: 34404331
[TBL] [Abstract][Full Text] [Related]
7. Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma?
Sahin H; Sari ME; Cuylan ZF; Haberal AN; Sirvan L; Coban G; Yalcin I; Güngör T; Celik H; Meydanli MM; Ayhan A
Arch Gynecol Obstet; 2018 Apr; 297(4):1005-1013. PubMed ID: 29383437
[TBL] [Abstract][Full Text] [Related]
8. Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR.
Chien W; Tyner JW; Gery S; Zheng Y; Li LY; Gopinatha Pillai MS; Nam C; Bhowmick NA; Lin DC; Koeffler HP
J Ovarian Res; 2023 Apr; 16(1):80. PubMed ID: 37087441
[TBL] [Abstract][Full Text] [Related]
9. The clinical characteristics and outcomes of cases with pure ovarian clear cell, mixed type and high-grade serous adenocarcinoma.
Kucukgoz Gulec U; Paydas S; Guzel AB; Vardar MA; Khatib G; Gumurdulu D
Arch Gynecol Obstet; 2015 Oct; 292(4):923-9. PubMed ID: 25855053
[TBL] [Abstract][Full Text] [Related]
10. Treatment issues in clear cell carcinoma of the ovary: a different entity?
Pectasides D; Pectasides E; Psyrri A; Economopoulos T
Oncologist; 2006; 11(10):1089-94. PubMed ID: 17110628
[TBL] [Abstract][Full Text] [Related]
11. Demographic Clinical and Prognostic Factors of Primary Ovarian Adenocarcinomas of Serous and Clear Cell Histology-A Comparative Study.
Schnack TH; Høgdall E; Nedergaard L; Høgdall C
Int J Gynecol Cancer; 2016 Jan; 26(1):82-90. PubMed ID: 26569060
[TBL] [Abstract][Full Text] [Related]
12. Evidence for ethnic and environmental contributions to frequency of ovarian clear cell carcinoma.
Tay SK; Cheong MA
Aust N Z J Obstet Gynaecol; 2014 Jun; 54(3):225-30. PubMed ID: 24888594
[TBL] [Abstract][Full Text] [Related]
13. Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma.
Zhou H; Liu Q; Shi X; Liu Y; Cao D; Yang J
J Ovarian Res; 2020 Apr; 13(1):38. PubMed ID: 32295618
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.
Kawabata A; Yanaihara N; Nagata C; Saito M; Noguchi D; Takenaka M; Iida Y; Takano H; Yamada K; Iwamoto M; Kiyokawa T; Okamoto A
Gynecol Oncol; 2017 Sep; 146(3):609-614. PubMed ID: 28673661
[TBL] [Abstract][Full Text] [Related]
15. Translational genomics of ovarian clear cell carcinoma.
Khalique S; Lord CJ; Banerjee S; Natrajan R
Semin Cancer Biol; 2020 Apr; 61():121-131. PubMed ID: 31698086
[TBL] [Abstract][Full Text] [Related]
16. New therapies for clear cell ovarian carcinoma.
Stewart J; Cunningham N; Banerjee S
Int J Gynecol Cancer; 2023 Mar; 33(3):385-393. PubMed ID: 36878571
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the clinical characteristics and prognosis between clear cell carcinomas and high-grade serous ovarian carcinomas.
Dong S; Yu F; Liu Y; Yu X; Sun X; Wang W; Wang Y
Ginekol Pol; 2023; 94(10):792-798. PubMed ID: 36477777
[TBL] [Abstract][Full Text] [Related]
18. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes.
Tan TZ; Ye J; Yee CV; Lim D; Ngoi NYL; Tan DSP; Huang RY
EBioMedicine; 2019 Dec; 50():203-210. PubMed ID: 31761620
[TBL] [Abstract][Full Text] [Related]
19. Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix.
Ota Y; Koizume S; Nakamura Y; Yoshihara M; Takahashi T; Sato S; Myoba S; Ohtake N; Kato H; Yokose T; Miyagi E; Miyagi Y
Oncol Rep; 2021 Mar; 45(3):1023-1032. PubMed ID: 33650653
[TBL] [Abstract][Full Text] [Related]
20. Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma.
Zhu C; Xu Z; Zhang T; Qian L; Xiao W; Wei H; Jin T; Zhou Y
J Cancer; 2021; 12(8):2295-2316. PubMed ID: 33758607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
